BenevolentAI Stock

Equities

BAI

LU2355630455

Biotechnology & Medical Research

Market Closed - Euronext Amsterdam 11:35:08 2024-07-19 EDT 5-day change 1st Jan Change
0.6 EUR +5.26% Intraday chart for BenevolentAI -10.45% -44.44%

Financials

Sales 2024 * 28.19M 36.39M 33.45M 49.99M Sales 2025 * 22.66M 29.25M 26.88M 40.18M Capitalization 61.67M 79.62M 73.18M 109M
Net income 2024 * -26M -33.57M -30.85M -46.11M Net income 2025 * -30M -38.73M -35.6M -53.2M EV / Sales 2024 * 1.28 x
Net cash position 2024 * 25.58M 33.02M 30.35M 45.36M Net cash position 2025 * 90.74M 117M 108M 161M EV / Sales 2025 * -1.28 x
P/E ratio 2024 *
-3.05 x
P/E ratio 2025 *
-3.04 x
Employees 248
Yield 2024 *
-
Yield 2025 *
-
Free-Float 56.16%
More Fundamentals * Estimated data
Dynamic Chart
1 day+5.26%
1 week-10.45%
Current month+22.95%
1 month+13.21%
3 months-9.09%
6 months-24.05%
Current year-44.44%
More quotes
1 week
0.56
Extreme 0.56
0.70
1 month
0.47
Extreme 0.466
0.91
Current year
0.46
Extreme 0.46
1.41
1 year
0.46
Extreme 0.46
2.66
3 years
0.46
Extreme 0.46
10.00
5 years
0.46
Extreme 0.46
10.00
10 years
0.46
Extreme 0.46
10.00
More quotes
Managers TitleAgeSince
Founder 48 13-10-31
Director of Finance/CFO 46 -
Chief Tech/Sci/R&D Officer - 20-06-30
Members of the board TitleAgeSince
Director/Board Member 68 20-06-30
Director/Board Member 60 22-04-21
Director/Board Member 66 21-08-31
More insiders
Date Price Change Volume
24-07-19 0.6 +5.26% 92,236
24-07-18 0.57 -5.00% 10,774
24-07-17 0.6 0.00% 18,609
24-07-16 0.6 -12.02% 44,351
24-07-15 0.682 +1.79% 14,021

Real-time Euronext Amsterdam, July 19, 2024 at 11:35 am

More quotes
BenevolentAI is a leader in applying advanced AI to accelerate biopharma drug discovery. The Company serves patients by leveraging its proprietary and validated Benevolent PlatformTM that integrates AI and science to uncover new biology, predict novel targets and develop first-in-class or best-in-class drugs for complex diseases. By applying proprietary advanced AI tools, in combination with in-house scientific expertise and wet-lab facilities, BenevolentAI is well-positioned to identify and accelerate novel drug discovery. The Company's business model presents multiple routes for value creation including discovery collaborations with pharma companies like AstraZeneca and Merck, and advancing in-house pipelines to inflection points.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.5058 GBP
Average target price
1.241 GBP
Spread / Average Target
+145.37%
Consensus

Quarterly revenue - Rate of surprise